Boston, MA 02/05/2014 (wallstreetpr) – Pfizer Inc. (NYSE:PFE) recently announced the successive trial of its new drug that claims to be effective and reliable in the treatment of mild pain. Nektar Therapeutics on the other hand is sneaking from behind with immense pressure with its innovative approach that is sure to give Pfizer a run for its money. Pfizer setbacks begun with the rejection of its new drug remoxy. This was later resolved with the company meeting primary efficacy endpoint in its late trial stages. The drug making company is also inline to introduce a new drug into the market which has passed tests that will be used to address issues of breast cancer in women.
Pfizer Ex Dividend
Pfizer Inc. (NYSE:PFE) has announced that its plans to begin the trading of its ex dividend as of February 5, 2014 with a cash dividend of $0.26 expected to be paid on March 4, 2014. Shareholders who will have purchased the company’s stock prior to the date of the ex-dividend will be eligible for cash dividend payment. The offer is expected to represent an increase of up to 8.33% compared to the prior’s quarter.
Pfizer current market status
Pfizer Inc. (NYSE:PFE) which commands a market cap of $205.97 billion closed trading on Tuesday evening at a high of $31.44 a massive increase of 2.75%. The company’s shares are currently priced at 13.48X the full year forecasted earnings, this essentially means they are a bit expensive compared to the industries 9.7X earnings. Pfizer consensus earnings are at a high of $0.55 per share compared to that of year ago, its stock has a dividend yield of 3.5% wit. The shares are currently rated as a buy in 7 analysts firms with only 1 analyst rating it as a sell and 4 as a hold. The average traded shares per day for the company stands at 24.3 million.
